Drug intelligence / Profile preview

Aerofor

Development stage: Unknown
Lead developer: AeroRx Therapeutics
Modality: Small Molecules
Administration: Inhalation

Overview

Aerofor is a branded generic inhalation therapy containing formoterol, a long-acting beta-2 adrenergic receptor agonist (LABA). It is manufactured by Teriak, a pharmaceutical company based in Tunisia. The drug is indicated for the maintenance treatment of asthma and the management of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). By selectively stimulating beta-2 adrenergic receptors in the lungs, Aerofor promotes bronchodilation through the relaxation of bronchial smooth muscle, providing long-lasting relief from respiratory symptoms. It is typically administered via a metered-dose inhaler or similar inhalation device.

Brand names: Aerofor
Other names: formoterol

Targets

ADRB2 (β2)ADRB3 (β3)ADRB1 (β1)

Beyond the preview

Go deeper on Aerofor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aerofor.

Explore the full profile